CARDIOLOGY NOTES
The Small Vessels, The Big Picture
Understanding Microvascular Disease and Why It Is Frequently Missed
A Cardiologist's Perspective
When people think about heart disease, they tend to think about blockages — plaques building up in the large coronary arteries that are visible on an angiogram and treatable with stents or bypass surgery. That picture is accurate, but incomplete.
A significant and frequently overlooked form of cardiovascular disease lives at a different scale entirely: in the small vessels, the arterioles and capillaries that deliver oxygen to the heart muscle at the level of the tissue itself. Microvascular disease, also called coronary microvascular dysfunction (CMD), is real, consequential, and far more common than most patients are told.
What is Microvascular Disease | Limits of Standard Testing
Why it Matters Clinically
Microvascular disease causes real ischemia- a genuine reduction in oxygen supply to the heart muscle, and is associated with increased risk of heart failure, particularly heart failure with preserved ejection fraction (HFpEF), atrial fibrillation, and adverse cardiovascular events. Symptoms can be indistinguishable from those of obstructive coronary artery disease: chest tightness, shortness of breath with exertion, exercise intolerance.
Patients with this diagnosis often spend years seeking answers, undergoing repeated testing, and being told their heart appears structurally normal. The absence of obstructive disease on an angiogram is not the same as the absence of cardiovascular disease. This distinction deserves to be made explicitly and earlier.
Treatment and Management
Risk Factor Optimization Remains Central
The same risk factors that drive large-vessel atherosclerosis drive microvascular disease: hypertension, dyslipidemia, insulin resistance, smoking, physical inactivity, and chronic inflammation.
Aggressive management of these factors improves microvascular function as well as macrovascular outcomes. Blood pressure control is particularly important, as hypertension impairs endothelial function and promotes vascular remodeling at the microvascular level.
Targeted Pharmacologic Options
Several medication classes have demonstrated benefit in microvascular disease specifically. Ranolazine improves anginal symptoms in patients with CMD. ACE inhibitors and angiotensin receptor blockers support endothelial function. Statins have pleiotropic effects beyond LDL lowering that appear to benefit the microvasculature.
More recently, SGLT2 inhibitors have shown compelling evidence of benefit in HFpEF, a condition closely linked to microvascular dysfunction suggesting a relevant therapeutic role in this population.
Treatment is individually tailored and benefits from care at centers with specific expertise in this area. If you or someone you care for has been told their chest pain symptoms lack a clear explanation after standard workup, CMD warrants consideration and discussion.
Asking the Right Questions
If you have symptoms consistent with coronary disease such as exertional chest pain, dyspnea, unexplained fatigue and a standard evaluation has not yielded answers, it is appropriate to ask specifically whether microvascular disease has been considered and whether additional testing is warranted. The field has advanced considerably, and patients no longer need to accept uncertainty as a final answer.
The small vessels tell an important part of the cardiovascular story. They deserve to be part of the conversation.
Fatty liver disease is not a bystander condition. It is a window into the metabolic environment your heart and arteries are living in.